Ossiam Increases Stake in DaVita Inc. (NYSE:DVA)

Ossiam increased its position in DaVita Inc. (NYSE:DVA - Free Report) by 71.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,105 shares of the company's stock after acquiring an additional 3,378 shares during the quarter. Ossiam's holdings in DaVita were worth $1,212,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Invesco Ltd. boosted its stake in DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after purchasing an additional 275,284 shares during the period. JPMorgan Chase & Co. boosted its stake in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares during the period. Amundi boosted its stake in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after purchasing an additional 240,126 shares during the period. Epoch Investment Partners Inc. bought a new position in DaVita in the 4th quarter worth approximately $55,100,000. Finally, KBC Group NV boosted its stake in DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after purchasing an additional 2,636 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Up 0.0 %

NYSE:DVA traded up $0.01 during midday trading on Friday, hitting $139.57. 600,714 shares of the company traded hands, compared to its average volume of 841,722. The firm's fifty day moving average is $146.50 and its 200-day moving average is $155.24. DaVita Inc. has a 12-month low of $131.27 and a 12-month high of $179.60. The firm has a market capitalization of $11.17 billion, a P/E ratio of 13.00, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DVA. Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. Finally, StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, DaVita has a consensus rating of "Hold" and a consensus target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.